THE 1 CONVENIENCE OF A DAILY PILL
The first combination of its kind —
a single daily pill, along with diet and exercise1
a single daily pill, along with diet and exercise1
RETHINK THE MATH to manage T2DM
3 Ways of Powerful Efficacy1
Powered by EMPA + LINA with proven CV-HF Renal outcomes2-5
References
-
GLYXAMBI® India pack insert version. 15 May 2024.
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.
-
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.
-
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166.
-
Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801-1802.